Next Article in Journal
Multidrug-Resistant Micro-Organisms Associated with Urinary Tract Infections in Orthopedic Patients: A Retrospective Laboratory-Based Study
Next Article in Special Issue
Genomic Variations in Drug Resistant Mycobacterium tuberculosis Strains Collected from Patients with Different Localization of Infection
Previous Article in Journal
Effects of a Paediatric Antimicrobial Stewardship Program on Antimicrobial Use and Quality of Prescriptions in Patients with Appendix-Related Intraabdominal Infections
Previous Article in Special Issue
Genetic Variation Putatively Associated with Mycobacterium tuberculosis Resistance to Perchlozone, a New Thiosemicarbazone: Clues from Whole Genome Sequencing and Implications for Treatment of Multidrug-Resistant Tuberculosis
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Antibiotics
Volume 10
Issue 1
10.3390/antibiotics10010006
antibiotics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Identification of Mutations Conferring Tryptanthrin Resistance to Mycobacterium smegmatis

by
Svetlana G. Frolova
1,2,
Ksenia M. Klimina
1,3,
Ravinder Kumar
4,
Aleksey A. Vatlin
1,5,
Deepak B. Salunke
4,6,
Pravin Kendrekar
7,
Valery N. Danilenko
1 and
Dmitry A. Maslov
1,*
1
Laboratory of Bacterial Genetics, Vavilov Institute of General Genetics, Russian Academy of Sciences, Moscow 119333, Russia
2
Moscow Institute of Physics and Technology (State University), Dolgoprudny 141701, Russia
3
Department of Molecular Biology and Genetics, Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, Moscow 119435, Russia
4
Department of Chemistry and Centre of Advanced Studies in Chemistry, Panjab University, Chandigarh 160014, India
5
Department of Design of Functional Foods and Nutritionology, Moscow State University of Food Production, Moscow 109316, Russia
6
National Interdisciplinary Centre of Vaccine, Immunotherapeutics and Antimicrobials, Panjab University, Chandigarh 160014, India
7
Unit for Drug Discovery Research (UDDR), Department of Health Sciences, Central University of Technology, Bloemfontein 9300, South Africa
*
Author to whom correspondence should be addressed.
Antibiotics 2021, 10(1), 6; https://doi.org/10.3390/antibiotics10010006
Submission received: 3 December 2020 / Revised: 21 December 2020 / Accepted: 22 December 2020 / Published: 23 December 2020
(This article belongs to the Special Issue Antimicrobial Resistance of Mycobacterium Tuberculosis: Old and New Drugs)
Browse Figure
Versions Notes

Abstract

:
Tuberculosis (TB), caused by Mycobacterium tuberculosis, is a global burden, responsible for over 1 million deaths annually. The emergence and spread of drug-resistant M. tuberculosis strains (MDR-, XDR- and TDR-TB) is the main challenge in global TB-control, requiring the development of novel drugs acting on new biotargets, thus able to overcome the drug-resistance. Tryptanthrin is a natural alkaloid, with great therapeutic potential due to its simple way of synthesis and wide spectrum of biological activities including high bactericidal activity on both drug-susceptible and MDR M. tuberculosis strains. InhA was suggested as the target of tryptanthrins by in silico modeling, making it a promising alternative to isoniazid, able to overcome drug resistance provided by katG mutations. However, neither the mechanism of action of tryptanthrin nor the mechanism of resistance to tryptanthrins was ever confirmed in vitro. We show that the MmpS5-MmpL5 efflux system is able to provide resistance to tryptanthrins using an in-house test-system. Comparative genomic analysis of spontaneous tryptanthrin-resistant M. smegmatis mutants showed that mutations in MSMEG_1963 (EmbR transcriptional regulator) lead to a high-level resistance, while those in MSMEG_5597 (TetR transcriptional regulator) to a low-level one. Mutations in an MFS transporter gene (MSMEG_4427) were also observed, which might be involved in providing a basal level of tryptanthrins-resistance.

1. Introduction

Mycobacterium tuberculosis is the causative agent of tuberculosis (TB), one of the most dangerous infectious diseases. According to the World Health Organization, about 10 million people fell ill with TB and more than 1.4 million people died in 2019, which makes TB one of the top 10 causes of death worldwide, with an overall number of TB-infected people reaching 2 billion. The global TB incidence rate has fallen by 9% between 2015 and 2020, though it failed to reach the goal of a 20% reduction stated by the WHO TB end strategy, with the COVID-19 pandemic becoming one of the possible reasons affecting further progress of this goal. Drug-resistant TB is a serious obstacle to a successful cure and requiring prolonged and expensive treatment. Globally, in 2019, 3.3% of new TB cases and 17.7% of previously treated TB cases had multidrug-resistance (MDR-TB, defined as TB resistant to rifampicin and isoniazid) [1]. M. tuberculosis drug resistance is usually defined by mutations in genes encoding drug biotargets, activators of pro-drugs, and efflux pumps’ transcriptional regulators [2].
The emergence and spread of M. tuberculosis strains with extensive (XDR-TB, defined as MDR with additional resistance to second-line injectables and a fluoroquinolone) and total drug resistance (TDR-TB, defined as TB resistant to all anti-TB drugs) urge for new approaches in design and the screening of novel antitubercular drugs [3,4,5,6].
Tryptanthrin (indolo[2,1-b]quinazoline-6,12-dione) is a natural alkaloid compound, belonging to indoloquinazoline antibiotics, and was first isolated from a Chinese herb Strobilanthescusia Kuntze [7]. Tryptanthrin (1a, Scheme 1) has great therapeutic potential due to its simple way of synthesis and wide spectrum of biological activities such as antifungal, antibacterial, and antiprotozoal [7,8,9]. Tryptanthrin and its analogs were shown to be anti-tumor agents both in vitro on cancer cell lines [10,11] and in vivo on rat model [12], being potent inhibitors of indoleamine 2,3-dioxygenase (IDO1) [13], tryptophan 2,3-dioxygenase (TDO) and indoleamine 2,3-dioxygenase 2 (IDO2) [14]. The anti-inflammatory action of tryptanthrin was shown to be effective for treating intestine disorders in murine models [15,16] and inhibiting allergic responses in vitro [17].
Tryptanthrin was first described as a potential anti-TB agent by Mitscher and Baker, with a MIC of 1 µg/mL, preserving its activity on MDR strains [18]. According to docking studies, tryptanthrin exhibits a high affinity towards M. tuberculosis enoyl-acyl carrier protein reductase (InhA) [19]—an enzyme playing a key role in the biosynthesis of mycolic acids, a primary target of isoniazid [20]. Isoniazid is a prodrug, that needs to be activated by the catalase-peroxidase encoded by katG [21], and the majority of drug-resistance conferring mutations occur in katG rather than inhA [22]. Thus, tryptanthrins, which do not need to be activated by katG, could represent promising anti-TB drugs, that could overcome katG-mediated drug resistance to isoniazid. Despite the in silico studies showing that tryptanthrins target InhA, the exact biotarget of these compounds, as well as the mycobacterial resistance mechanism, have not yet been described in vitro.
This paper describes the mechanisms of mycobacterial resistance to tryptanthrins by evaluating the biological activity of tryptanthrin and its fluoro-substituted derivative (8-Fluorotryptanthrin, 1b) [19,23] on Mycobacterium smegmatis strains, obtaining their spontaneous drug-resistant mutants, their whole-genomic sequencing, and comparative genomic analysis.

2. Results

2.1. Synthesis of Tryptanthrin Analogs

Isatin and 5-fluoroisatin (Scheme 1) on condensation with isatoic anhydride in the presence of triethylamine in refluxing toluene for four hours resulted in the formation of tryptanthrin (1a) and 8-fluorotryptanthrin (1b), respectively [24]. The formation of the desired compounds was confirmed using NMR spectroscopic analysis and the purity was analyzed using HPLC (Figures S1–S5).

2.2. Tryptanthrins May Be Subjected to MmpS5-MmpL5 Mediated Efflux

The MmpS5-MmpL5 efflux system was previously shown to provide resistance to multiple drugs in different mycobacterial species [25,26,27], including resistance to bedaquiline in clinical M. tuberculosis isolates [28]. We determined the minimal inhibitory concentrations (MICs) of 1a and 1b on three M. smegmatis strains differing in mmpS5-mmL5 operon expression levels: mc2 155, Δmmp5 and atr9c. M. smegmatis Δmmp5 is an M. smegmatis mc2 155 derivative, carrying a 2828 bp. deletion in the mmpS5-mmpL5 operon, and hypersensitive to drugs, subjected to MmpS5-MmpL5 efflux, such as imidazo[1,2-b][1,2,4,5]tetrazines [29]. M. smegmatis atr9c, on the contrary, carries a mutation in MSMEG_1380, leading to overexpression of mmpS5-mmpL5 genes, and is resistant to drugs, subjected to MmpS5-MmpL5 efflux [27]. Thus, comparing MIC values on these three strains can be used for prescreening antimycobacterial drugs candidates for potential MmpS5-MmpL5 efflux mediated drug resistance.
M. smegmatis atr9c turned out to be resistant to compound 1a, while M. smegmatis Δmmp5 was hypersensitive to 1b (Table 1), showing that MmpS5-MmpL5 efflux was involved in resistance to tryptanthrins, but with different specificity.

2.3. Mutations in Transcriptional Regulators and a Transporter Gene May Confer Resistance to Tryptanthrins

As mmpS5-mmpL5 overexpression led to a relatively high level of resistance to tryptanthrin (1a), other spontaneous mutations in MSMEG_1380 could also result in 1a resistance. Thus, we selected 1b for further generation of spontaneous drug-resistant mutants. M. smegmatis Δmmp5 was used as the parent strain together with M. smegmatis mc2 155, as it could also help to avoid mmpS5-mmpL5-mediated drug resistance, and to reveal other resistance-conferring mutations.
We were able to obtain spontaneous 1b-resistant mutants derived from both M. smegmatis mc2 155 and M. smegmatis Δmmp5 at a frequency of 6.3 × 10−7 and 1.6 × 10−7, respectively. We randomly selected eight mutants (four from each group) for further analysis.
Whole-genomic sequencing and comparative genomic analysis allowed us to identify a number of non-synonymous mutations, which may confer tryptanthrin-resistance to M. smegmatis (Table 2).
We identified three nonsynonymous single nucleotide polymorphisms (SNPs) in four strains in MSMEG_1963, encoding an EmbR transcriptional regulatory protein, leading to a high-level resistance to both tryptanthrins (Table 2). Interestingly, this protein’s homolog in M. tuberculosis (Rv1267c) was shown to be involved in ethambutol resistance [30]. However, the MIC values of ethambutol were revealed to be the same on the strains carrying MSMEG_1963 mutation and the control strains (0.1 µg/mL), showing no cross-resistance.
The MSMEG_5597 had three different mutations in four strains: one frameshift mutation, one SNP, leading to prolonged protein synthesis, and an insertion of ISMsm1 transposon (genes MSMEG_1728-MSMEG_1730). These mutations were associated with low-level resistance to tryptanthrins (Table 2).
We also identified one SNP in all the M. smegmatis mc2 155 derived mutants in MSMEG_4427, encoding a Major Facilitator Superfamily (MFS) transporter. BLAST search identified Rv1250 as its homolog in M. tuberculosis with a 32% identity and 46% similarity in the amino acid sequence. Rv1250 was reported to be overexpressed with other efflux pump genes in MDR M. tuberculosis strains [31,32,33,34] and can be upregulated in the presence of drugs [35]. Besides the effect of overexpression of Rv1250 on drug resistance, unique SNPs in this gene were also found in XDR-TB strains [36].

3. Discussion

Tryptanthrins attracted attention as potential anti-tuberculosis drug candidates due to their high in vitro activity against both drug-susceptible and MDR M. tuberculosis strains, and their low toxicity [18,23,37]. InhA was suggested as the target of tryptanthrins by in silico modeling [19], making it a promising alternative to isoniazid, able to overcome drug resistance provided by katG mutations [22]. However, neither the mechanism of action nor the mechanism of resistance to tryptanthrins was studied in vitro, which is an essential step of drug development in the post-genomic era [38]. We describe several potential ways of M. smegmatis developing resistance to tryptanthrins.
MmpS5-MmpL5 is an important multidrug-efflux-pump system, which is able to provide mycobacteria resistance to multiple drugs such as bedaquiline, clofazimine [39], azoles [25], thiacetazone derivatives [26], and imidazo[1,2-b][1,2,4,5]tetrazines [27]. We used a test-system involving two M. smegmatis recombinant strains to show that mmpS5-mmpL5 operon overexpression provides resistance to tryptanthrin (1a), while deletion of mmpS5-mmpL5 operon leads to hypersensitivity to 8-fluorotryptanthrin (1b). Compound 1a thus may be subjected to MmpS5-MmpL5-mediated efflux more efficiently, as mmpS5-mmpL5 overexpression leads to resistance to this compound. However, the MmpS5-MmpL5 is able to provide a basal level of resistance to the compound 1b as well, though it is not increased with this systems’ overexpression. Apparently, the basal level of resistance to 1b is more specifically mediated by MmpS5-MmpL5 efflux, while the basal level of resistance to 1a may be less specific and provided by other efflux pumps as well. Thus, the MmpS5-MmpL5 system was able to provide resistance to both tryptanthrins (though at different levels), and it should be considered when developing other tryptanthrin derivatives, as potentially leading to cross-resistance with other drugs.
Whole-genomic sequences of spontaneous M. smegmatis mutants, obtained on 1b, but resistant to both compounds revealed mutations in three genes, which may be a clue for drug-resistance or action mechanism.
The mutation in a transcriptional regulator (MSMEG_1963) led to a high level of resistance to both compounds in the strains where it was present. The homolog of this gene in M. tuberculosis is described as the transcriptional regulator of the embCAB operon, with mutations in it leading to ethambutol resistance [30]. However, the lack of cross-resistance with ethambutol in M. smegmatis may show a different function of this gene.
Mutations found in MSMEG_5597 (frameshift, insertion of a transposon, and a longer protein product), associated with low-level resistance to tryptanthrins, apparently lead to a disruption of its function. MSMEG_1730 encodes a TetR family transcriptional regulator. TetR family proteins are involved in the transcriptional control of multidrug efflux pumps, pathways for the biosynthesis of antibiotics, response to osmotic stress and toxic chemicals, control of catabolic pathways, differentiation processes, and pathogenicity [40]. Disruption of a TetR repressor’s function usually leads to the upregulation of some other genes. However, this gene does not have any efflux pump genes located nearby on the chromosome. The MSMEG_5596 located upstream of MSMEG_5597, which may be regulated by the latter, encodes an SDR family oxidoreductase, which might be involved in tryptanthrin modification, though this requires additional investigation.
While the mutation in a transcriptional regulator most likely leads to a change in expression levels of its regulated genes, the mutation found in the MSMEG_4427 encoding MFS transporter may be directly altering its specificity to enhance tryptanthrins’ efflux or alter cell wall permeability. This kind of transporters is responsible for the efflux of a wide spectrum of compounds with different chemical and physical properties. MFS transporters use the energy stored in an electrochemical gradient across the membrane [41]. Importantly, MFS transporters play a significant role in bacterial intrinsic drug resistance [42]. Though in most cases this type of transporters in M. tuberculosis was reported to confer drug resistance by their overexpression [31,32,33,34], SNPs associated with XDR were also reported for Rv1250 (homolog of MSMEG_4427) [36]. The strains carrying the mutation in MSMEG_4427 showed a higher level of resistance to tryptanthrins, when combined with the MSMEG_5597 mutation (mc2-8, mc2-16 and mc2-18 compared to Δmmp5-10). However, the mc2-strains also had a functional copy of mmpS5-mmpL5 operon, able to provide a higher basal level of resistance. Thus, the impact of MSMEG_4427 mutation on tryptanthrins resistance is less evident than of those in MSMEG_1963 and MSMEG_5597.
Though the individual impact of each mutation on tryptanthrins resistance is yet to be established by overexpression studies and targeted mutants’ construction, we believe that the results presented in this paper can be a clue to further investigation of tryptanthrins’ mechanism of action and mycobacterial resistance to these compounds. Other challenges in tryptanthrins’ development as anti-tuberculosis drug candidates include the design of more soluble derivatives with higher in vivo potencies [43].

4. Materials and Methods

4.1. Synthetic Procedures of Tryptanthrin Analogs

Indolo[2,1-b]quinazoline-6,12-dione (Tryptanthrin, 1a): Isatin (1 g, 6.796 mmol, 1 eq) was dissolved in toluene (20 mL). Et3N (4.74 mL, 33.98 mmol, 5 eq) was added and the reaction mixture was stirred for 15 min. Isatoic anhydride (1.66 g, 10.19 mmol, 1.5 eq) was added to the reaction mixture and the resulting mixture was refluxed at 110 °C for 4 h. Toluene was evaporated under reduced pressure and the product obtained was extracted in ethyl acetate. The ethyl acetate layer was washed with water followed by brine and dried over anhydrous Na2SO4 and concentrated under vacuum to yield a crude yellow product which was subjected to a flash column chromatography to isolate pure product (eluent: 15% ethyl acetate in hexanes). Yellow solid, Rf = 0.35 (30% Ethyl acetate/Hexanes) 1H NMR (400 MHz, CDCl3) δ 8.63 (d, J = 8.1 Hz, 1H), 8.44 (dd, J = 7.9, 1.2 Hz, 1H), 8.03 (dd, J = 8.1, 0.7 Hz, 1H), 7.92 (dd, J = 7.6, 0.7 Hz, 1H), 7.89–7.83 (m, 1H), 7.79 (td, J = 8.0, 1.3 Hz, 1H), 7.71–7.65 (m, 1H), 7.43 (td, J = 7.6, 0.8 Hz, 1H). HPLC Purity- 98.20%.
8-Fluoro-indolo[2,1-b]quinazoline-6,12-dione (8-Fluorotryptanthrin, 1b): Compound 1b was synthesized following the same procedure as described for 1a using 5-flouroisatin. The synthesis and purification were optimized for 1 g scale. Yellow solid, Rf = 0.3 (30% Ethyl acetate/Hexanes); 1H NMR (500 MHz, CDCl3) δ 8.58 (dd, J = 8.7, 4.0 Hz, 1H), 8.35 (d, J = 7.8 Hz, 1H), 7.95 (d, J = 8.0 Hz, 1H), 7.79 (t, J = 7.6 Hz, 1H), 7.61 (t, J = 7.5 Hz, 1H), 7.51 (dd, J = 6.4, 2.5 Hz, 1H), 7.41 (td, J = 8.6, 2.6 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 181.7, 162.1, 157.9, 146.5, 135.3, 130.9, 130.5, 127.6, 124.9, 124.8, 123.7, 119.7, 119.7, 112.2, 112.0. HPLC Purity- 99.04%.

4.2. Bacterial Strains and Growth Conditions

All M. smegmatis strains were grown in Middlebrook 7H9 medium (Himedia, Mumbai, India) supplemented with oleic albumin dextrose catalase (OADC, Himedia, Mumbai, India), 0.1% Tween-80 (v/v), and 0.4% glycerol (v/v) or on solid medium M290 Soyabean Casein Digest Agar (Himedia, Mumbai, India). Bacterial cultures in liquid medium were incubated in the Multitron incubator shaker (Infors HT, Basel, Switzerland) at 37 °C and 250 rpm.

4.3. MIC Determination

Minimal inhibitory concentrations (MICs) of the studied compounds on M. smegmatis were determined in a liquid medium. M. smegmatis strains were cultured overnight in 7H9 medium, then diluted in the proportion of 1:200 in fresh medium (to approximately OD600 = 0.05). 196 µL of the diluted culture were poured in sterile non-treated 96-well flat-bottom culture plates (Eppendorf, Hamburg, Germany) and 4 µL of serial two-fold dilutions of the tested compounds in DMSO were added to the wells to reach final concentrations ranging from 0.5 to 32 µg/mL, the maximum soluble concentrations of 1a and 1b were also tested (49.3 and 53.2 µg/mL respectively, equivalent to 0.2 mM). For ethambutol MIC determination, the serial two-fold dilutions ranged from 0.05 to 6.4 µg/mL. The plates were incubated at 37 °C and 250 rpm for 48 h. The MIC was determined as the lowest concentration of the compound with no visible bacterial growth.

4.4. Generation of Resistant Mutants and Their Phenotype Characterization

M. smegmatis mc2 155 and M. smegmatis Δmmp5 were grown in a liquid medium to reach OD600 = 2.8 (~4 × 108 CFU/mL). 200 µL of each bacterial culture were plated on agar plates containing 1b at a final concentration of 16 µg/mL (4× MIC for M. smegmatis mc2 155 and 16× MIC M. smegmatis Δmmp5). Plates were incubated in a thermostat at 30 °C for three days until the emergence of single colonies. The colonies from two plates for each strain were counted to determine the frequency of drug-resistant mutants’ emergence. Serial 10-fold dilutions of each bacterial culture were plated on compound-free plates to determine the exact titer. The mutants’ resistance phenotypes were confirmed by streaking several colonies on M290 plates containing 16 µg/mL of 1b. The parental strains (M. smegmatis mc2 155 and Δmmp5) were used as control. Tryptanthrins’ MICs on resistant mutants were determined in a liquid medium as described above.

4.5. Mycobacterial DNA Extraction

Mycobacterial genomic DNA was isolated from 10 mL by enzymatic lysis as described by Belisle et al. [44], after preliminary isolation, DNA was treated with RNase A (Thermo Fisher Scientific, Waltham, MA, USA) and extracted in the phenol-chloroform-isoamyl alcohol solution (25:24:1).

4.6. Whole-Genomic Sequencing

A total of 250 ng genomic DNA was taken for shotgun sequencing library preparation. After DNA sonication on Covaris S220 System (Covaris, Woburn, MA, USA), the size (400–500 bp) and quality of fragmented samples were assessed on Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA, USA) according to the manufacturer’s manual. NEBNext Ultra II DNA Library Prep Kit (New England Biolabs, Ipswich, MA, USA) was used for pair-ended library preparation, and NEBNext Multiplex Oligos kit for Illumina (96 Index Primers, New England Biolabs, Ipswich, MA, USA) was used for libraries’ indexing. The libraries were quantified by Quant-iT DNA Assay Kit, High Sensitivity (Thermo Scientific, Waltham, MA, USA). DNA sequencing (2 × 125 bp) was performed on the HiSeq 2500 platform (Illumina, San Diego, CA, USA) according to the manufacturer’s recommendations.

4.7. Whole-Genomic Data Analysis

The obtained reads’ quality was assessed with FastQC (v. 0.11.9) [45], which revealed good quality for further assembly. The reads were aligned to the reference genome (NC_008596.1, PRJNA57701) using the BWA-MEM algorithm [46]. The pileup was generated by mpileup (-B -f) in SAMtools [47]. Single nucleotide variants were called by running mpileup2snp (--min-avg-qual 30 --min-var-freq 0.80 --p-value 0.01 --output-vcf 1 --variants 1) in VarScan (v. 2.3.9) [48]. Annotation was created using vcf_annotate.pl (developed by Natalya Mikheecheva of the Laboratory of Bacterial Genetics, Vavilov Institute of General Genetics). The non-synonymous single nucleotide variants found within open reading frames and absent in the wild-type strain were selected for further analysis.
For de novo assembly, reads were trimmed with Trimmomativ (v. 0.39) [49] with the following settings, as recommended in SPAdes manual: ILLUMINACLIP:NexteraPE-PE.fa:2:30:10 LEADING:3 TRAILING:3 SLIDINGWINDOW:4:20 MINLEN:36. SPAdes (v. 3.14.1) [50] with --isolate setting was used for de novo assembly. BLAST (https://blast.ncbi.nlm.nih.gov) was used to detect the transposon insert in M. smegmatis mc2-16 and mc2-18 genomes, as well as for the homology search.

4.8. Data Availability

The raw sequencing data (SRA), as well as the WGS data for M. smegmatis strains obtained in this study, are publicly available in NCBI GenBank (BioProject ID: PRJNA672137).

5. Conclusions

Tryptanthrins are considered promising antituberculosis agents, active on both drug-susceptible and MDR-TB strains, with InhA predicted as their primary target. In this research we show that MmpS5-MmpL5-mediated efflux can provide mycobacteria resistance to tryptanthrins and may thus lead to cross-resistance with other drugs. We also revealed mutations in MSMEG_1963 (EmbR transcriptional regulator) as providing high-level resistance to tryptanthrins, and those in MSMEG_5597 (TetR transcriptional regulator) as leading to a low-level one. Mutations in an MFS transporter gene (MSMEG_4427) might be involved in providing a basal level of tryptanthrins-resistance.

Supplementary Materials

The following are available online at https://www.mdpi.com/2079-6382/10/1/6/s1, Figure S1: Compound 1a, 1H NMR (400 MHz) in CDCl3, Figure S2: Compound 1a, HPLC, Figure S3: Compound 1b, 1H NMR (500 MHz) in CDCl3, Figure S4: Compound 1b, 13C NMR (126 MHz) in CDCl3, Figure S5: Compound 1b, HPLC.

Author Contributions

Conceptualization, D.A.M., D.B.S. and P.K.; methodology, D.A.M.; investigation, S.G.F., K.M.K., A.A.V. and R.K.; resources, K.M.K., V.N.D., D.B.S., P.K. and D.A.M.; writing—original draft preparation, S.G.F., D.A.M. and D.B.S.; writing—review and editing, D.A.M. and D.B.S.; supervision, V.N.D.; project administration, D.A.M.; funding acquisition, D.A.M. All authors have read and agreed to the published version of the manuscript.

Funding

The MmpS5-MmpL5 efflux specificity studies were funded by the Russian Science Foundation (RSF grant no. 17-75-20060-P), while the remaining biological studies were funded by a grant of the President of Russian Federation for young scientists—candidates of science (grant no. MK-797.2020.4).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Acknowledgments

We thank the Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency for the opportunity to use computational and sequencing resources.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. World Health Organization. World Health Organization Global Tuberculosis Report 2020; World Health Organization: Geneva, Switzerland, 2020; pp. 1–232. [Google Scholar]
  2. Hameed, H.M.A.; Islam, M.M.; Chhotaray, C.; Wang, C.; Liu, Y.; Tan, Y.; Li, X.; Tan, S.; Delorme, V.; Yew, W.W.; et al. Molecular Targets Related Drug Resistance Mechanisms in MDR-, XDR-, and TDR-Mycobacterium tuberculosis Strains. Front. Cell. Infect. Microbiol. 2018, 8, 114. [Google Scholar] [CrossRef] [PubMed]
  3. Caminero, J.A.; Sotgiu, G.; Zumla, A.; Migliori, G.B. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect. Dis. 2010, 10, 621–629. [Google Scholar] [CrossRef]
  4. Gandhi, N.R.; Nunn, P.; Dheda, K.; Schaaf, H.S.; Zignol, M.; van Soolingen, D.; Jensen, P.; Bayona, J. Multidrug-resistant and extensively drug-resistant tuberculosis: A threat to global control of tuberculosis. Lancet 2010, 375, 1830–1843. [Google Scholar] [CrossRef]
  5. Klopper, M.; Warren, R.M.; Hayes, C.; van Pittius, N.C.G.; Streicher, E.M.; Müller, B.; Sirgel, F.A.; Chabula-Nxiweni, M.; Hoosain, E.; Coetzee, G.; et al. Emergence and Spread of Extensively and Totally Drug-Resistant Tuberculosis, South Africa. Emerg. Infect. Dis. 2013, 19, 449–455. [Google Scholar] [CrossRef] [Green Version]
  6. Velayati, A.A.; Farnia, P.; Farahbod, A.M. Overview of drug-resistant tuberculosis worldwide. Int. J. Mycobacteriol. 2016, 5 (Suppl. 1), S161. [Google Scholar] [CrossRef] [Green Version]
  7. Honda, G.; Tabata, M. Isolation of antifungal principle tryptanthrin, from Strobilanthes cusia O. Kuntze. Planta Med. 1979, 36, 85–90. [Google Scholar] [CrossRef]
  8. Honda, G.; Tosirisuk, V.; Tabata, M. Isolation of an antidermatophytic, tryptanthrin, from indigo plants, Polygonum tinctorium and Isatis tinctoria. Planta Med. 1980, 38, 275–276. [Google Scholar] [CrossRef]
  9. Scovill, J.; Blank, E.; Konnick, M.; Nenortas, E.; Shapiro, T. Antitrypanosomal activities of tryptanthrins. Antimicrob. Agents Chemother. 2002, 46, 882–883. [Google Scholar] [CrossRef] [Green Version]
  10. Kimoto, T.; Hino, K.; Koya-Miyata, S.; Yamamoto, Y.; Takeuchi, M.; Nishizaki, Y.; Micallef, M.J.; Ushio, S.; Iwaki, K.; Ikeda, M.; et al. Cell differentiation and apoptosis of monocytic and promyelocytic leukemia cells (U-937 and HL-60) by tryptanthrin, an active ingredient of Polygonum tinctorium Lour. Pathol. Int. 2001, 51, 315–325. [Google Scholar] [CrossRef]
  11. Sharma, V.M.; Prasanna, P.; Seshu, K.V.A.; Renuka, B.; Rao, C.V.L.; Kumar, G.S.; Narasimhulu, C.P.; Babu, P.A.; Puranik, R.C.; Subramanyam, D.; et al. Novel indolo[2,1-b]quinazoline analogues as cytostatic agents: Synthesis, biological evaluation and structure-activity relationship. Bioorg. Med. Chem. Lett. 2002, 12, 2303–2307. [Google Scholar] [CrossRef]
  12. Koya-Miyata, S.; Kimoto, T.; Micallef, M.J.; Hino, K.; Taniguchi, M.; Ushio, S.; Iwaki, K.; Ikeda, M.; Kurimoto, M. Prevention of azoxymethane-induced intestinal tumors by a crude ethyl acetate-extract and tryptanthrin extracted from Polygonum tinctorium Lour. Anticancer Res. 2001, 21, 3295–3300. [Google Scholar] [PubMed]
  13. Yang, S.; Li, X.; Hu, F.; Li, Y.; Yang, Y.; Yan, J.; Kuang, C.; Yang, Q. Discovery of tryptanthrin derivatives as potent inhibitors of indoleamine 2,3-dioxygenase with therapeutic activity in Lewis lung cancer (LLC) tumor-bearing mice. J. Med. Chem. 2013, 56, 8321–8331. [Google Scholar] [CrossRef] [PubMed]
  14. Yang, D.; Zhang, S.; Fang, X.; Guo, L.; Hu, N.; Guo, Z.; Li, X.; Yang, S.; He, J.C.; Kuang, C.; et al. N-Benzyl/Aryl Substituted Tryptanthrin as Dual Inhibitors of Indoleamine 2,3-Dioxygenase and Tryptophan 2,3-Dioxygenase. J. Med. Chem. 2019, 62, 9161–9174. [Google Scholar] [CrossRef]
  15. Micallef, M.J.; Iwaki, K.; Ishihara, T.; Ushio, S.; Aga, M.; Kunikata, T.; Koya-Miyata, S.; Kimoto, T.; Ikeda, M.; Kurimoto, M. The natural plant product tryptanthrin ameliorates dextran sodium sulfate-induced colitis in mice. Int. Immunopharmacol. 2002, 2, 565–578. [Google Scholar] [CrossRef]
  16. Takei, Y.; Kunikata, T.; Aga, M.; Inoue, S.-I.; Ushio, S.; Iwaki, K.; Ikeda, M.; Kurimoto, M. Tryptanthrin inhibits interferon-gamma production by Peyer’s patch lymphocytes derived from mice that had been orally administered staphylococcal enterotoxin. Biol. Pharm. Bull. 2003, 26, 365–367. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  17. Iwaki, K.; Ohashi, E.; Arai, N.; Kohno, K.; Ushio, S.; Taniguchi, M.; Fukuda, S. Tryptanthrin inhibits Th2 development, and IgE-mediated degranulation and IL-4 production by rat basophilic leukemia RBL-2H3 cells. J. Ethnopharmacol. 2011, 134, 450–459. [Google Scholar] [CrossRef]
  18. Mitscher, L.A.; Baker, W. Tuberculosis: A search for novel therapy starting with natural products. Med. Res. Rev. 1998, 18, 363–374. [Google Scholar] [CrossRef]
  19. Tripathi, A.; Wadia, N.; Bindal, D.; Jana, T. Docking Studies on Novel Alkaloid Tryptanthrin and Its Analogues against Enoyl-acyl Carrier Protein Reductase (InhA) of Mycobacterium tuberculosis; NISCAIR-CSIR: New Delhi, India, 2012. [Google Scholar]
  20. Banerjee, A.; Dubnau, E.; Quemard, A.; Balasubramanian, V.; Um, K.S.; Wilson, T.; Collins, D.; de Lisle, G.; Jacobs, W.R. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 1994, 263, 227–230. [Google Scholar] [CrossRef] [Green Version]
  21. Zhang, Y.; Heym, B.; Allen, B.; Young, D.; Cole, S. The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 1992, 358, 591–593. [Google Scholar] [CrossRef]
  22. Seifert, M.; Catanzaro, D.; Catanzaro, A.; Rodwell, T.C. Genetic Mutations Associated with Isoniazid Resistance in Mycobacterium tuberculosis: A Systematic Review. PLoS ONE 2015, 10, e0119628. [Google Scholar] [CrossRef] [Green Version]
  23. Kaur, R.; Manjal, S.K.; Rawal, R.K.; Kumar, K. Recent synthetic and medicinal perspectives of tryptanthrin. Bioorg. Med. Chem. 2017, 25, 4533–4552. [Google Scholar] [CrossRef] [PubMed]
  24. Baker, W.R.; Mitscher, L.A.; Corp, P. Indolo[2,1-Biquinazoline-6,12-dione Antibacterial Compounds and Methods of Use Thereof. U.S. Patent 5,441,955, 15 August 1995. [Google Scholar]
  25. Milano, A.; Pasca, M.R.; Provvedi, R.; Lucarelli, A.P.; Manina, G.; de Ribeiro, A.L.J.L.; Manganelli, R.; Riccardi, G. Azole resistance in Mycobacterium tuberculosis is mediated by the MmpS5-MmpL5 efflux system. Tuberculosis 2009, 89, 84–90. [Google Scholar] [CrossRef] [PubMed]
  26. Halloum, I.; Viljoen, A.; Khanna, V.; Craig, D.; Bouchier, C.; Brosch, R.; Coxon, G.; Kremer, L. Resistance to Thiacetazone Derivatives Active against Mycobacterium abscessus Involves Mutations in the MmpL5 Transcriptional Repressor MAB_4384. Antimicrob. Agents Chemother. 2017, 61, NP246. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  27. Maslov, D.A.; Shur, K.V.; Vatlin, A.A.; Danilenko, V.N. MmpS5-MmpL5 Transporters Provide Mycobacterium smegmatis Resistance to imidazo[1,2-b][1,2,4,5]tetrazines. Pathogens 2020, 9, 166. [Google Scholar] [CrossRef] [Green Version]
  28. Chawla, K.; Martinez, E.; Kumar, A.; Shenoy, V.P.; Sintchenko, V. Whole-genome sequencing reveals genetic signature of bedaquiline resistance in a clinical isolate of Mycobacterium tuberculosis. J. Glob. Antimicrob. Resist. 2018, 15, 103–104. [Google Scholar] [CrossRef]
  29. Shur, K.V.; Frolova, S.G.; Akimova, N.I.; Danilenko, V.N.; Maslov, D.A. A Test-System for in vitro Screening Antimycobacterial Drug Candidates for MmpS5-MmpL5 Mediated Drug Resistance. Russ. J. Genet. 2021, 57, 114–116, In Press. [Google Scholar]
  30. Sharma, K.; Gupta, M.; Krupa, A.; Srinivasan, N.; Singh, Y. EmbR, a regulatory protein with ATPase activity, is a substrate of multiple serine/threonine kinases and phosphatase in Mycobacterium tuberculosis. FEBS J. 2006, 273, 2711–2721. [Google Scholar] [CrossRef]
  31. Li, G.; Zhang, J.; Guo, Q.; Jiang, Y.; Wei, J.; Zhao, L.-L.; Zhao, X.; Lu, J.; Wan, K. Efflux pump gene expression in multidrug-resistant Mycobacterium tuberculosis clinical isolates. PLoS ONE 2015, 10, e0119013. [Google Scholar] [CrossRef] [Green Version]
  32. Narang, A.; Giri, A.; Gupta, S.; Garima, K.; Bose, M.; Varma-Basil, M. Contribution of putative efflux pump genes to isoniazid resistance in clinical isolates of Mycobacterium tuberculosis. Int. J. Mycobacteriol. 2017, 6, 177–183. [Google Scholar]
  33. Ghajavand, H.; Kamakoli, M.K.; Khanipour, S.; Dizaji, S.P.; Masoumi, M.; Jamnani, F.R.; Fateh, A.; Yaseri, M.; Siadat, S.D.; Vaziri, F. Scrutinizing the drug resistance mechanism of multi- and extensively-drug resistant Mycobacterium tuberculosis: Mutations versus efflux pumps. Antimicrob. Resist. Infect. Control. 2019, 8, 70–78. [Google Scholar] [CrossRef]
  34. AlMatar, M.; Var, I.; Kayar, B.; Köksal, F. Differential Expression of Resistant and Efflux Pump Genes in MDR-TB Isolates. Endocr. Metab. Immune Disord. Drug Targets 2020, 20, 271–287. [Google Scholar] [CrossRef] [PubMed]
  35. Umar, F.; Hatta, M.; Husain, D.R.; Natzir, R.; Dwiyanti, R.; Junita, A.R.; Primaguna, M.R. The effect of anti-tuberculosis drugs therapy on mRNA efflux pump gene expression of Rv1250 in Mycobacterium tuberculosis collected from tuberculosis patients. New Microbes New Infect. 2019, 32, 100609. [Google Scholar] [CrossRef] [PubMed]
  36. Kanji, A.; Hasan, R.; Ali, A.; Zaver, A.; Zhang, Y.; Imtiaz, K.; Shi, W.; Clark, T.G.; McNerney, R.; Phelan, J.; et al. Single nucleotide polymorphisms in efflux pumps genes in extensively drug resistant Mycobacterium tuberculosis isolates from Pakistan. Tuberculosis 2017, 107, 20–30. [Google Scholar] [CrossRef] [PubMed]
  37. Popov, A.; Klimovich, A.; Styshova, O.; Moskovkina, T.; Shchekotikhin, A.; Grammatikova, N.; Dezhenkova, L.; Kaluzhny, D.; Deriabin, P.; Gerasimenko, A.; et al. Design, synthesis and biomedical evaluation of mostotrin, a new water soluble tryptanthrin derivative. Int. J. Mol. Med. 2020, 1–12. [Google Scholar] [CrossRef] [PubMed]
  38. Cooper, C.B. Development of Mycobacterium tuberculosis Whole Cell Screening Hits as Potential Antituberculosis Agents. J. Med. Chem. 2013, 56, 7755–7760. [Google Scholar] [CrossRef] [PubMed]
  39. Hartkoorn, R.C.; Uplekar, S.; Cole, S.T. Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2014, 58, 2979–2981. [Google Scholar] [CrossRef] [Green Version]
  40. Ramos, J.L.; Martínez-Bueno, M.; Molina-Henares, A.J.; Terán, W.; Watanabe, K.; Zhang, X.; Gallegos, M.T.; Brennan, R.; Tobes, R. The TetR family of transcriptional repressors. Microbiol. Mol. Biol. Rev. 2005, 69, 326–356. [Google Scholar] [CrossRef] [Green Version]
  41. Li, P.; Gu, Y.; Li, J.; Xie, L.; Li, X.; Xie, J. Mycobacterium tuberculosis Major Facilitator Superfamily Transporters. J. Membr. Biol. 2017, 250, 573–585. [Google Scholar] [CrossRef]
  42. Fluman, N.; Bibi, E. Bacterial multidrug transport through the lens of the major facilitator superfamily. Biochim. Biophys. Acta Proteins Proteom. 2009, 1794, 738–747. [Google Scholar] [CrossRef]
  43. Kaur, P.; Agarwal, S.; Datta, S. Delineating bacteriostatic and bactericidal targets in mycobacteria using IPTG inducible antisense expression. PLoS ONE 2009, 4, e5923. [Google Scholar] [CrossRef] [Green Version]
  44. Belisle, J.T.; Mahaffey, S.B.; Hill, P.J. Isolation of Mycobacterium Species Genomic DNA. In Mycobacteria Protocols; Methods in Molecular Biology; Humana Press: Totowa, NJ, USA, 2010; Volume 465, pp. 1–12. [Google Scholar]
  45. Andrews, S. FastQC: A Quality Control Tool for High Throughput Sequence Data. 2010. Available online: http://www.bioinformatics.babraham.ac.uk/projects/fastqc (accessed on 18 April 2020).
  46. Li, H.; Durbin, R. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics 2010, 26, 589–595. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  47. Li, H. A statistical framework for SNP calling, mutation discovery, association mapping and population genetical parameter estimation from sequencing data. Bioinformatics 2011, 27, 2987–2993. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  48. Koboldt, D.C.; Zhang, Q.; Larson, D.E.; Shen, D.; McLellan, M.D.; Lin, L.; Miller, C.A.; Mardis, E.R.; Ding, L.; Wilson, R.K. VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 2012, 22, 568–576. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  49. Bolger, A.M.; Lohse, M.; Usadel, B. Trimmomatic: A flexible trimmer for Illumina sequence data. Bioinformatics 2014, 30, 2114–2120. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  50. Bankevich, A.; Nurk, S.; Antipov, D.; Gurevich, A.A.; Dvorkin, M.; Kulikov, A.S.; Lesin, V.M.; Nikolenko, S.I.; Pham, S.; Prjibelski, A.D.; et al. SPAdes: A new genome assembly algorithm and its applications to single-cell sequencing. J. Comput. Biol. 2012, 19, 455–477. [Google Scholar] [CrossRef] [Green Version]
Antibiotics 10 00006 sch001 550
Scheme 1. Synthetic route for the preparation of tryptanthrins. Reagents and conditions: (a) triethylamine, toluene, 110 °C, 4 h, 90%.
Scheme 1. Synthetic route for the preparation of tryptanthrins. Reagents and conditions: (a) triethylamine, toluene, 110 °C, 4 h, 90%.
Antibiotics 10 00006 sch001
Table
Table 1. MICs of 1a and 1b on M. smegmatis strains.
Table 1. MICs of 1a and 1b on M. smegmatis strains.
CompoundM. smegmatis Strains MICs
Mwmc2 1551Δmmp5 2atr9c3
µg/mLµMµg/mLµMµg/mLµM
1a248.24416.1416.11664.4
1b266.2341513.8415
1 Wild type strain. 2 Strain lacking mmpS5-mmpL5 operon. 3 Strain with mmpS5-mmpL5 operon overexpression.
Table
Table 2. Genetic and phenotypic characteristics of M. smegmatis mutant strains.
Table 2. Genetic and phenotypic characteristics of M. smegmatis mutant strains.
StrainGeneMICs, µg/mL
MSMEG_1963MSMEG_5597MSMEG_44271a1b
NucleotideAmino
Acid		NucleotideAmino
Acid		NucleotideAmino
Acid
mc2-8w.t.w.t.C49>CTGframeshiftCTG>CGGL236R1616
mc2-10CGT>TGTR893Cw.t.w.t.CTG>CGGL236R>49>53
mc2-16w.t.w.t.Transposon insertionCTG>CGGL236R168
mc2-18w.t.w.t.Transposon insertionCTG>CGGL236R328
Δmmp5-1CGC>TGCR523Cw.t.w.t.w.t.w.t.>49>53
Δmmp5-3CGC>TGCR523Cw.t.w.t.w.t.w.t.>49>53
Δmmp5-6CGC>CTCR523Lw.t.w.t.w.t.w.t.>49>53
Δmmp5-10w.t.w.t.TGA>CGAStop207Rw.t.w.t.84
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Frolova, S.G.; Klimina, K.M.; Kumar, R.; Vatlin, A.A.; Salunke, D.B.; Kendrekar, P.; Danilenko, V.N.; Maslov, D.A. Identification of Mutations Conferring Tryptanthrin Resistance to Mycobacterium smegmatis. Antibiotics 2021, 10, 6. https://doi.org/10.3390/antibiotics10010006

AMA Style

Frolova SG, Klimina KM, Kumar R, Vatlin AA, Salunke DB, Kendrekar P, Danilenko VN, Maslov DA. Identification of Mutations Conferring Tryptanthrin Resistance to Mycobacterium smegmatis. Antibiotics. 2021; 10(1):6. https://doi.org/10.3390/antibiotics10010006

Chicago/Turabian Style

Frolova, Svetlana G., Ksenia M. Klimina, Ravinder Kumar, Aleksey A. Vatlin, Deepak B. Salunke, Pravin Kendrekar, Valery N. Danilenko, and Dmitry A. Maslov. 2021. "Identification of Mutations Conferring Tryptanthrin Resistance to Mycobacterium smegmatis" Antibiotics 10, no. 1: 6. https://doi.org/10.3390/antibiotics10010006

APA Style

Frolova, S. G., Klimina, K. M., Kumar, R., Vatlin, A. A., Salunke, D. B., Kendrekar, P., Danilenko, V. N., & Maslov, D. A. (2021). Identification of Mutations Conferring Tryptanthrin Resistance to Mycobacterium smegmatis. Antibiotics, 10(1), 6. https://doi.org/10.3390/antibiotics10010006

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop